BLAINTRAVENOUSPOWDERPriority Review
Approved
Jun 2019
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
21
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 8h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
POLIVY (polatuzumab vedotin-piiq) is an antibody-drug conjugate (ADC) targeting CD79b on B cells, approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma after at least two prior therapies. The drug combines a monoclonal antibody with MMAE, a microtubule-disrupting payload, delivered intracellularly to kill dividing B cells via apoptosis.
$0.001BPart D
PeakProduct is at peak lifecycle stage with modest Part D utilization (76 claims in 2023), suggesting stable but limited commercial momentum typical of specialized oncology therapies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (21)
Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan Trial
Started Mar 2027
27 enrolled
Mantle Cell Lymphoma
TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
Started Nov 2026
30 enrolled
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaLymphoma+1 more
Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination Therapy
Started Dec 2025
200 enrolled
Diffuse Large B Cell Lymphoma (DLBCL)
Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
Started Jun 2025
38 enrolled
Diffuse Large B-Cell Lymphoma
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Started Apr 2025
594 enrolled
Lymphoma, Large B-Cell, Diffuse
Worked on POLIVY at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.